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Targeting Kinase Networks in Glioblastoma
Deepraj Sarmah1, Gregory Smith2, Samuel Dillon1, Pamela Bretcher1, Marc R. Birtwistle1,2
1Department

of Chemical and Biomolecular Engineering, Clemson University, Clemson, SC 29634
2 Icahn School of Medicine at Mount Sinai, New York, NY 10029

Glioblastoma (GBM) is one of the most invasive and deadliest of cancers and
accounts for at least 50% of all primary tumors in the brain. It is a difficult disease
to treat because of its invasive nature, heterogeneity, development of cell
resistance to treatment, and because the selectivity of the blood-brain barrier
allows very select few molecules into the brain.
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The challenge is to design effective combination therapies for cancers, which is a
difficult task to perform experimentally, because of the large number of such
possible drug combinations.
We seek to target the network of kinases in GBM with 27 Blood Brain Barrier
penetrant kinase inhibitors and analyze subsequent phosphoproteomic data. We
seek to use the multiple off targets of kinase inhibitors to study the network effects
of the drug rather than just a particular kinase. We plan to use Dynamic Modular
Response, a mathematical model to analyze the various phosphoproteomic data
obtained from GBM cell lines treated with Blood Brain Barrier penetrant Kinase
Inhibitors, to build the network and predict drug combinations.
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4 criteria to select kinases, 2 Pharmacological, 2 Biological

Dynamic Modular Response
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Figure 1: Signature gene cluster of
three subtypes of GBM

Figure 5: Experiments to determine network structure in GBM: A. List of Drugs
and most important kinases in GBM determined through pharmacological and
biological criteria. B. Cell culture of GBM cell lines treated with respective drugs C.
Imaging of cells treated with different drugs to observe proliferation, movement and
cell death D. Cell lysates of cells treated with different drugs for phosphoproteomic
analysis E. Phosphoproteomic data for the relevant kinases in cells treated with
multiple drugs F. Construction of kinase network G. Prediction and testing of drug
combinations

Figure 2: Kinase targets of different
kinase inhibitors across the human
kinome
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Figure 3: Tight junctions and
gatekeeper proteins in the Blood
Brain Barrier prevent most drugs
from reaching the brain
Figure 4: A. Perturbation of nodes and time course experiments to determine
edge weights B. Predicted Edge weights vs Actual Edge weights for simulated
experiments with 0, 0.1, 0.2 and 0.5 random noise C. Determining edge weights
of ERK-AKT interaction in MCF10A cells under Insulin+ EGF stimulus.
Perturbations used are MEK inhibition and AKT inhibition. D. Structure and
interactions of a 3 node system

This project should allow us to better rationalize combination therapy by better
understanding how kinase drug targets are connected. If successful, we will lay a
foundation for rational design of effective combination therapy not only for GBM but
other cancer types.
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